Trial Profile
A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Semzuvolimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors United BioPharma
- 21 Apr 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 12 May 2022 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 12 May 2022 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.